Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05587036
Other study ID # S66407
Secondary ID 2021-006814-35
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date February 2, 2023
Est. completion date December 2024

Study information

Verified date May 2024
Source Universitaire Ziekenhuizen KU Leuven
Contact Lukas Van Oudenhove, MD, PhD
Phone +32 16 33 01 47
Email lukas.vanoudenhove@kuleuven.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, triple-blind, placebo-controlled study on the effect of rifaximin on psychobiological functions in healthy men.


Description:

This study is a randomized, triple-blind, placebo-controlled, interventional trial aiming to elucidate the impact of rifaximin-induced gut microbiota alteration to the psychobiological functioning of healthy men. The intervention will be performed in a parallel group design where one group will receive rifaximin (Targaxan 550 mg) twice daily for two weeks (treatment arm), while the other group will receive placebo (placebo arm). Primary objective: to test the effect of rifaximin on stress sensitivity and fear-related processes Secondary objective: to determine the mediating and/or moderating factors that underlie rifaximin-induced psychobiological changes


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 2024
Est. primary completion date November 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures 2. Proficiency in English and/or Dutch 3. Healthy with no intestinal and/or psychological complaints 4. Access to a -18°C freezer (i.e. ordinary household freezer) 5. Male participants 6. Age 18-50 years 7. BMI 18.5-25 kg/m2 Exclusion Criteria: 1. Participant has a history of previous or current neurological, psychiatric, gastrointestinal or endocrine disorder 2. Any disorder, which in the Investigator's opinion might jeopardize the participant's safety or compliance with the protocol 3. Any prior or concomitant treatment(s) that might jeopardize the participant's safety or that would compromise the integrity of the Trial 4. Participation in an interventional Trial with an investigational medicinal product (IMP) or device 5. Hypersensitivity to the active substance rifaximin, to any rifamycin (e.g. rifampicin or rifabutin) or any of the excipients 6. Current or recent medication use 7. Use of antibiotics within three months preceding the study 8. Current or recent (1-month) infection (e.g. common cold, influenza, COVID-19, etc.) 9. Previous or current substance/alcohol dependence or abuse (>2 units per day or 14 units per week) 10. One or more diagnoses based on the mini international neuropsychiatric interview (MINI-S) 11. One or more diagnoses based on ROME IV for gastrointestinal disorders 12. Smoking 13. Night-shift work 14. Adherence to special diets (e.g. vegan, vegetarian, weight-loss, lactose-free, gluten-free, etc.) 15. Use of pre- or probiotics within one month preceding the study 16. Previous experience with any of the tasks used in the study (not including questionnaires) 17. Color vision deficiency (colorblindness) 18. Magnetic Resonance Imaging (MRI) contraindications, including claustrophobia, severe back problems, conditions that would interfere with MRI scanning (e.g. cochlear implant, metal fragments in eyes, metallic body inclusion, or other metal implanted in the body), and if the participant does not want to be informed of incidental findings that might be found during imaging.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rifaximin
Rifaximin oral tablet, 550 mg, twice daily, two-weeks
Dietary Supplement:
Placebo
Placebo oral tablet, twice daily, two-weeks

Locations

Country Name City State
Belgium UZ/KU Leuven Leuven

Sponsors (1)

Lead Sponsor Collaborator
Universitaire Ziekenhuizen KU Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Other Fecal gut microbiota profile Assessing gut microbiota profile before and after intervention Throughout study completion, on average 1 year
Other Serum short-chain fatty acid levels Quantification of serum SCFA (µM) before and after intervention Throughout study completion, on average 1 year
Other Cytokine levels Quantification of inflammatory cytokines (pg/ml) before and after intervention Throughout study completion, on average 1 year
Other C-reactive protein levels Quantification of C-reactive protein levels (ng/ml) before and after intervention Throughout study completion, on average 1 year
Other Heart rate variability Assessing heart rate variability (ms) with ECG before and after intervention Throughout study completion, on average 1 year
Other Heart rate Assessing heartbeat (bpm) with a blood pressure monitor before and after intervention Throughout study completion, on average 1 year
Other Blood pressure Assessing blood pressure (systolic/diastolic mmHg) with a blood pressure monitor before and after intervention Throughout study completion, on average 1 year
Other Brain metabolite concentration Relative quantification of brain metabolites (mmol/L) using 1H-Magnetic Resonance Spectroscopy before and after intervention Throughout study completion, on average 1 year
Primary Stress sensitivity (biological) Biological stress sensitivity is measured by quantifying cortisol levels (ng/ml) from multiple saliva samples taken before, during, and after a stress task performed during the pre-intervention and post-intervention visit. Throughout study completion, on average 1 year
Primary Stress sensitivity (psychological) Psychological stress sensitivity is measured through subjective stress reports of the participants using the visual analogue scale (VAS). VAS scorings are taken before, during, and after a stress task performed during the pre-intervention and post-intervention visit. Throughout study completion, on average 1 year
Primary Fear (biological) Fear-related processes will be explored using a computerized task. Biological fear response is measured using skin conductance, and a skin conductance response (µS) is calculated . Throughout study completion, on average 1 year
Primary Fear (psychological) Fear-related processes will be explored using a computerized task. Psychological fear response is measured subjectively by asking participants to indicate their expectancy score of an aversive stimulus. Throughout study completion, on average 1 year
Secondary Positive and Negative Affect Schedule (PANAS) Assessing ratings on the subscales of PANAS, positive and negative affect, before and after intervention. PA subscale scores range between 10-50, with higher scores indicating better outcome. NA subscale scores range between 10-50, with higher scores indicating worse outcome. Throughout study completion, on average 1 year
Secondary Perceived Stress Scale (PSS) Assessing ratings on PSS before and after intervention. PSS scores range between 0-40 with higher scores indicating worse outcome. Throughout study completion, on average 1 year
Secondary Gastrointestinal Symptom Rating Scale (GSRS) Assessing ratings on the subscales of GSRS and its total score before and after intervention. It has 5 subscales (Reflux, Diarrhea, Constipation, Abdominal Pain, and Indigestion Syndrome). Subscale scores range from 1 to 7 and higher scores indicates a worse outcome. Throughout study completion, on average 1 year
Secondary Leiden Index of Depression Sensitivity (LEIDS-R) Assessing ratings on the subscales of LEIDS-R and its total score before and after intervention. This is a self-report on cognitive reactivity comprised of 34 items with six subscales. Hopelessness/suicidality; Acceptance/Coping; Aggression; Control/Perfectionism; Risk Aversion; Rumination. Throughout study completion, on average 1 year
Secondary State-Trait Anxiety Inventory, State Anxiety Subscale (STAI-S) Assessing ratings on the momentary (state) anxiety subscale of STAI before and after intervention. This is a self-report comprised of 20 questions specifically for state anxiety, rated on a 4-point scale. State anxiety is rated with anxiety absent and anxiety present questions. Anxiety absent questions constitute the absence of anxiety in a statement like, "I feel secure." Anxiety present questions represent the presence of anxiety in a statement like "I feel worried." The 4-point scale are as follows: 1 'not at all', 2 'somewhat', 3 'moderately so', and 4 'very much so'. Throughout study completion, on average 1 year
Secondary Brain response to stress Brain response (brain oxygenation level-dependent signals) to a fMRI-adapted stress task will be measured before and after intervention Throughout study completion, on average 1 year
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1